摘要
Abstract
Objective To observe the clinical effect of Carboplatin+Albumin Bound Paclitaxel+Bevacizumab in the treatment of ovarian cancer.Methods Fifty patients with ovarian cancer admitted to the Department of Gynecology,Wuwei People's Hospital from April 2021 to April 2024 were selected as the study objects and divided into two groups using the random number table method.The control group(25 cases)received treatment with Carboplatin+Albumin Bound Paclitaxel,and the experimental group(25 cases)received treatment with Carboplatin+Albumin Bound Paclitaxel+Bevacizumab.The treatment effect and tumor marker levels were compared between the two groups.Results The total effective rate of treatment in the experimental group was better than that in the control group(P<0.05).Before treatment,there were no statistically significant differences in the levels of carcinoembryonic antigen(CEA),alpha fetoprotein(AFP),tissue peptide antigen(TPA),and carbohydrate antigen 125(CA125)between the two groups(P>0.05).After treatment,the levels of CEA,AFP,TPA,and CA125 in both groups decreased,and the levels of CEA,AFP,TPA,and CA125 in the experimental group were lower than those in the control group(P<0.05).Conclusion The treatment of patients with ovarian cancer with Carboplatin+Albumin Bound Paclitaxel+Bevacizumab can effectively improve the treatment effect and has high clinical application value.关键词
卡铂/白蛋白结合型紫杉醇/贝伐珠单抗/卵巢癌Key words
Carboplatin/Albumin Bound Paclitaxel/Bevacizumab/Ovarian cancer分类
医药卫生
